PCSK9 and stroke disorder: In a recent meta-analysis of 67 randomized controlled trials (RCTs) including 259,429 participants PCSK9 inhibitors plus statin significantly reduced the risk of non-fatal MI (RR 0.82, 95% CI 0.72–0.93, p = 0.003) or stroke (RR 0.74, 95% CI 0.65–0.85, p < 0.001) (Chaiyasothi et al., 2019).